The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study

E. Fabiani, C. Catassi, S. De Rosa, N. Litwin, H. Ellemunter, J. Eder, L. Gandolfi, R. Pratesi, S. Sulkanen, M. Máki, A. Baquey, T. Lamireau, F. Bienvenu, G. Beaune, J. Schmitz, A. M. Yamamoto, J. Schellscheidt, K. P. Zimmer, M. Stern, F. M. StevensM. Kearns, C. Catassi, E. Fabiani, M. Baldassarre, G. Di Bitonto, M. Masi, R. Lazzari, P. Lionetti, G. Massai, M. Cingolani, E. Castellano, C. Sferlazzas, G. Di Pasquale, G. Barera, P. Roggero, F. Balli, L. Viola, R. Troncone, G. Iovine, G. Guariso, M. Plebani, F. Cataldo, P. Greco, F. Cavataio, M. Di Gregorio, G. L. De Angelis, M. Manfredi, G. Ferraro, G. Castellucci, C. Romano, A. Caccamo, F. Colistro, M. Castro, F. Viola, M. Barbato, M. Vascotto, G. Morgese, N. Ansaldi-Balocco, M. Di Leo, A. Ventura, T. Not, C. J J Mulder, J. Kerckhaert, C. Czismadia, M. L. Mearin, I. Polanco, M. M. Esteban, G. K T Holmes, V. Mendez, A. Fasano, K. Horvath, S. Guandalini, H. Andrew, E. Bravi, M. Caradonna

Research output: Contribution to journalArticle

Abstract

Objectives So far the reliability of the anti-tissue transglutaminase (anti-tTG) test for the diagnosis of coeliac disease has mostly been evaluated using slightly different enzyme-linked immunosorbent assays (ELISAs) in selected and usually small groups of patients. The aims of this study were: (1) to evaluate the reliability of the IgA anti-tTG antibodies for the diagnosis of coeliac disease; and (2) to define the sensitivity and specificity of a commercially available kit for the anti-tTG antibodies' quantitative determination. Design Each centre in this international multi-centre study collected sera from three groups of subjects: coeliac disease patients at the onset of (1) or on a gluten-free diet for at least 12 months (2); disease and healthy controls (3). Methods The anti-tTG antibodies were determined in duplicate using an ELISA-based commercially available kit (Eu-tTG Eurospital, Trieste, Italy). Results The following overall cases and controls have been enrolled: (1) 399 subjects with active coeliac disease; (2) 351 treated coeliac disease cases; (3) 432 controls. The centralized re-testing was performed on: (1) group a: 176 patients with active coeliac disease (mean anti-tTG, 21 arbitrary units [AU]); (2) group b: 172 treated coeliac disease cases (mean anti-tTG, 5 AU); (3) group c: 206 controls (mean anti-tTG, 3 AU). In active coeliacs, the anti-tTG antibodies showed a significant progressive decrease with age, while in controls an opposite trend was found. In active coeliac disease patients, the anti-tTG antibodies were significantly higher in coeliacs with a grade III enteropathy than in those showing a grade II lesion. In treated coeliacs, the mean anti-tTG values were significantly lower in patients strictly adhering to a gluten-free diet than in those reporting dietary transgressions. The sensitivity and the specificity of the Eu-tTG assay were 90% and 96%, respectively. Conclusion The results of this study show that the commercially available test for the anti-tTG antibodies' determination is a reproducible and valuable tool for the diagnosis and follow up of coeliac disease.

Original languageEnglish
Pages (from-to)659-665
Number of pages7
JournalEuropean Journal of Gastroenterology and Hepatology
Volume13
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

Celiac Disease
Antibodies
Serum
Abdomen
Gluten-Free Diet
transglutaminase 2
anti-IgA
Enzyme-Linked Immunosorbent Assay
Sensitivity and Specificity
Italy

Keywords

  • Coeliac disease
  • Screening
  • Serology
  • Tissue transglutaminase

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study. / Fabiani, E.; Catassi, C.; De Rosa, S.; Litwin, N.; Ellemunter, H.; Eder, J.; Gandolfi, L.; Pratesi, R.; Sulkanen, S.; Máki, M.; Baquey, A.; Lamireau, T.; Bienvenu, F.; Beaune, G.; Schmitz, J.; Yamamoto, A. M.; Schellscheidt, J.; Zimmer, K. P.; Stern, M.; Stevens, F. M.; Kearns, M.; Catassi, C.; Fabiani, E.; Baldassarre, M.; Di Bitonto, G.; Masi, M.; Lazzari, R.; Lionetti, P.; Massai, G.; Cingolani, M.; Castellano, E.; Sferlazzas, C.; Di Pasquale, G.; Barera, G.; Roggero, P.; Balli, F.; Viola, L.; Troncone, R.; Iovine, G.; Guariso, G.; Plebani, M.; Cataldo, F.; Greco, P.; Cavataio, F.; Di Gregorio, M.; De Angelis, G. L.; Manfredi, M.; Ferraro, G.; Castellucci, G.; Romano, C.; Caccamo, A.; Colistro, F.; Castro, M.; Viola, F.; Barbato, M.; Vascotto, M.; Morgese, G.; Ansaldi-Balocco, N.; Di Leo, M.; Ventura, A.; Not, T.; Mulder, C. J J; Kerckhaert, J.; Czismadia, C.; Mearin, M. L.; Polanco, I.; Esteban, M. M.; Holmes, G. K T; Mendez, V.; Fasano, A.; Horvath, K.; Guandalini, S.; Andrew, H.; Bravi, E.; Caradonna, M.

In: European Journal of Gastroenterology and Hepatology, Vol. 13, No. 6, 2001, p. 659-665.

Research output: Contribution to journalArticle

Fabiani, E, Catassi, C, De Rosa, S, Litwin, N, Ellemunter, H, Eder, J, Gandolfi, L, Pratesi, R, Sulkanen, S, Máki, M, Baquey, A, Lamireau, T, Bienvenu, F, Beaune, G, Schmitz, J, Yamamoto, AM, Schellscheidt, J, Zimmer, KP, Stern, M, Stevens, FM, Kearns, M, Catassi, C, Fabiani, E, Baldassarre, M, Di Bitonto, G, Masi, M, Lazzari, R, Lionetti, P, Massai, G, Cingolani, M, Castellano, E, Sferlazzas, C, Di Pasquale, G, Barera, G, Roggero, P, Balli, F, Viola, L, Troncone, R, Iovine, G, Guariso, G, Plebani, M, Cataldo, F, Greco, P, Cavataio, F, Di Gregorio, M, De Angelis, GL, Manfredi, M, Ferraro, G, Castellucci, G, Romano, C, Caccamo, A, Colistro, F, Castro, M, Viola, F, Barbato, M, Vascotto, M, Morgese, G, Ansaldi-Balocco, N, Di Leo, M, Ventura, A, Not, T, Mulder, CJJ, Kerckhaert, J, Czismadia, C, Mearin, ML, Polanco, I, Esteban, MM, Holmes, GKT, Mendez, V, Fasano, A, Horvath, K, Guandalini, S, Andrew, H, Bravi, E & Caradonna, M 2001, 'The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study', European Journal of Gastroenterology and Hepatology, vol. 13, no. 6, pp. 659-665. https://doi.org/10.1097/00042737-200106000-00008
Fabiani, E. ; Catassi, C. ; De Rosa, S. ; Litwin, N. ; Ellemunter, H. ; Eder, J. ; Gandolfi, L. ; Pratesi, R. ; Sulkanen, S. ; Máki, M. ; Baquey, A. ; Lamireau, T. ; Bienvenu, F. ; Beaune, G. ; Schmitz, J. ; Yamamoto, A. M. ; Schellscheidt, J. ; Zimmer, K. P. ; Stern, M. ; Stevens, F. M. ; Kearns, M. ; Catassi, C. ; Fabiani, E. ; Baldassarre, M. ; Di Bitonto, G. ; Masi, M. ; Lazzari, R. ; Lionetti, P. ; Massai, G. ; Cingolani, M. ; Castellano, E. ; Sferlazzas, C. ; Di Pasquale, G. ; Barera, G. ; Roggero, P. ; Balli, F. ; Viola, L. ; Troncone, R. ; Iovine, G. ; Guariso, G. ; Plebani, M. ; Cataldo, F. ; Greco, P. ; Cavataio, F. ; Di Gregorio, M. ; De Angelis, G. L. ; Manfredi, M. ; Ferraro, G. ; Castellucci, G. ; Romano, C. ; Caccamo, A. ; Colistro, F. ; Castro, M. ; Viola, F. ; Barbato, M. ; Vascotto, M. ; Morgese, G. ; Ansaldi-Balocco, N. ; Di Leo, M. ; Ventura, A. ; Not, T. ; Mulder, C. J J ; Kerckhaert, J. ; Czismadia, C. ; Mearin, M. L. ; Polanco, I. ; Esteban, M. M. ; Holmes, G. K T ; Mendez, V. ; Fasano, A. ; Horvath, K. ; Guandalini, S. ; Andrew, H. ; Bravi, E. ; Caradonna, M. / The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study. In: European Journal of Gastroenterology and Hepatology. 2001 ; Vol. 13, No. 6. pp. 659-665.
@article{0fb39e919cc446078af908ca035a87e0,
title = "The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study",
abstract = "Objectives So far the reliability of the anti-tissue transglutaminase (anti-tTG) test for the diagnosis of coeliac disease has mostly been evaluated using slightly different enzyme-linked immunosorbent assays (ELISAs) in selected and usually small groups of patients. The aims of this study were: (1) to evaluate the reliability of the IgA anti-tTG antibodies for the diagnosis of coeliac disease; and (2) to define the sensitivity and specificity of a commercially available kit for the anti-tTG antibodies' quantitative determination. Design Each centre in this international multi-centre study collected sera from three groups of subjects: coeliac disease patients at the onset of (1) or on a gluten-free diet for at least 12 months (2); disease and healthy controls (3). Methods The anti-tTG antibodies were determined in duplicate using an ELISA-based commercially available kit (Eu-tTG Eurospital, Trieste, Italy). Results The following overall cases and controls have been enrolled: (1) 399 subjects with active coeliac disease; (2) 351 treated coeliac disease cases; (3) 432 controls. The centralized re-testing was performed on: (1) group a: 176 patients with active coeliac disease (mean anti-tTG, 21 arbitrary units [AU]); (2) group b: 172 treated coeliac disease cases (mean anti-tTG, 5 AU); (3) group c: 206 controls (mean anti-tTG, 3 AU). In active coeliacs, the anti-tTG antibodies showed a significant progressive decrease with age, while in controls an opposite trend was found. In active coeliac disease patients, the anti-tTG antibodies were significantly higher in coeliacs with a grade III enteropathy than in those showing a grade II lesion. In treated coeliacs, the mean anti-tTG values were significantly lower in patients strictly adhering to a gluten-free diet than in those reporting dietary transgressions. The sensitivity and the specificity of the Eu-tTG assay were 90{\%} and 96{\%}, respectively. Conclusion The results of this study show that the commercially available test for the anti-tTG antibodies' determination is a reproducible and valuable tool for the diagnosis and follow up of coeliac disease.",
keywords = "Coeliac disease, Screening, Serology, Tissue transglutaminase",
author = "E. Fabiani and C. Catassi and {De Rosa}, S. and N. Litwin and H. Ellemunter and J. Eder and L. Gandolfi and R. Pratesi and S. Sulkanen and M. M{\'a}ki and A. Baquey and T. Lamireau and F. Bienvenu and G. Beaune and J. Schmitz and Yamamoto, {A. M.} and J. Schellscheidt and Zimmer, {K. P.} and M. Stern and Stevens, {F. M.} and M. Kearns and C. Catassi and E. Fabiani and M. Baldassarre and {Di Bitonto}, G. and M. Masi and R. Lazzari and P. Lionetti and G. Massai and M. Cingolani and E. Castellano and C. Sferlazzas and {Di Pasquale}, G. and G. Barera and P. Roggero and F. Balli and L. Viola and R. Troncone and G. Iovine and G. Guariso and M. Plebani and F. Cataldo and P. Greco and F. Cavataio and {Di Gregorio}, M. and {De Angelis}, {G. L.} and M. Manfredi and G. Ferraro and G. Castellucci and C. Romano and A. Caccamo and F. Colistro and M. Castro and F. Viola and M. Barbato and M. Vascotto and G. Morgese and N. Ansaldi-Balocco and {Di Leo}, M. and A. Ventura and T. Not and Mulder, {C. J J} and J. Kerckhaert and C. Czismadia and Mearin, {M. L.} and I. Polanco and Esteban, {M. M.} and Holmes, {G. K T} and V. Mendez and A. Fasano and K. Horvath and S. Guandalini and H. Andrew and E. Bravi and M. Caradonna",
year = "2001",
doi = "10.1097/00042737-200106000-00008",
language = "English",
volume = "13",
pages = "659--665",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study

AU - Fabiani, E.

AU - Catassi, C.

AU - De Rosa, S.

AU - Litwin, N.

AU - Ellemunter, H.

AU - Eder, J.

AU - Gandolfi, L.

AU - Pratesi, R.

AU - Sulkanen, S.

AU - Máki, M.

AU - Baquey, A.

AU - Lamireau, T.

AU - Bienvenu, F.

AU - Beaune, G.

AU - Schmitz, J.

AU - Yamamoto, A. M.

AU - Schellscheidt, J.

AU - Zimmer, K. P.

AU - Stern, M.

AU - Stevens, F. M.

AU - Kearns, M.

AU - Catassi, C.

AU - Fabiani, E.

AU - Baldassarre, M.

AU - Di Bitonto, G.

AU - Masi, M.

AU - Lazzari, R.

AU - Lionetti, P.

AU - Massai, G.

AU - Cingolani, M.

AU - Castellano, E.

AU - Sferlazzas, C.

AU - Di Pasquale, G.

AU - Barera, G.

AU - Roggero, P.

AU - Balli, F.

AU - Viola, L.

AU - Troncone, R.

AU - Iovine, G.

AU - Guariso, G.

AU - Plebani, M.

AU - Cataldo, F.

AU - Greco, P.

AU - Cavataio, F.

AU - Di Gregorio, M.

AU - De Angelis, G. L.

AU - Manfredi, M.

AU - Ferraro, G.

AU - Castellucci, G.

AU - Romano, C.

AU - Caccamo, A.

AU - Colistro, F.

AU - Castro, M.

AU - Viola, F.

AU - Barbato, M.

AU - Vascotto, M.

AU - Morgese, G.

AU - Ansaldi-Balocco, N.

AU - Di Leo, M.

AU - Ventura, A.

AU - Not, T.

AU - Mulder, C. J J

AU - Kerckhaert, J.

AU - Czismadia, C.

AU - Mearin, M. L.

AU - Polanco, I.

AU - Esteban, M. M.

AU - Holmes, G. K T

AU - Mendez, V.

AU - Fasano, A.

AU - Horvath, K.

AU - Guandalini, S.

AU - Andrew, H.

AU - Bravi, E.

AU - Caradonna, M.

PY - 2001

Y1 - 2001

N2 - Objectives So far the reliability of the anti-tissue transglutaminase (anti-tTG) test for the diagnosis of coeliac disease has mostly been evaluated using slightly different enzyme-linked immunosorbent assays (ELISAs) in selected and usually small groups of patients. The aims of this study were: (1) to evaluate the reliability of the IgA anti-tTG antibodies for the diagnosis of coeliac disease; and (2) to define the sensitivity and specificity of a commercially available kit for the anti-tTG antibodies' quantitative determination. Design Each centre in this international multi-centre study collected sera from three groups of subjects: coeliac disease patients at the onset of (1) or on a gluten-free diet for at least 12 months (2); disease and healthy controls (3). Methods The anti-tTG antibodies were determined in duplicate using an ELISA-based commercially available kit (Eu-tTG Eurospital, Trieste, Italy). Results The following overall cases and controls have been enrolled: (1) 399 subjects with active coeliac disease; (2) 351 treated coeliac disease cases; (3) 432 controls. The centralized re-testing was performed on: (1) group a: 176 patients with active coeliac disease (mean anti-tTG, 21 arbitrary units [AU]); (2) group b: 172 treated coeliac disease cases (mean anti-tTG, 5 AU); (3) group c: 206 controls (mean anti-tTG, 3 AU). In active coeliacs, the anti-tTG antibodies showed a significant progressive decrease with age, while in controls an opposite trend was found. In active coeliac disease patients, the anti-tTG antibodies were significantly higher in coeliacs with a grade III enteropathy than in those showing a grade II lesion. In treated coeliacs, the mean anti-tTG values were significantly lower in patients strictly adhering to a gluten-free diet than in those reporting dietary transgressions. The sensitivity and the specificity of the Eu-tTG assay were 90% and 96%, respectively. Conclusion The results of this study show that the commercially available test for the anti-tTG antibodies' determination is a reproducible and valuable tool for the diagnosis and follow up of coeliac disease.

AB - Objectives So far the reliability of the anti-tissue transglutaminase (anti-tTG) test for the diagnosis of coeliac disease has mostly been evaluated using slightly different enzyme-linked immunosorbent assays (ELISAs) in selected and usually small groups of patients. The aims of this study were: (1) to evaluate the reliability of the IgA anti-tTG antibodies for the diagnosis of coeliac disease; and (2) to define the sensitivity and specificity of a commercially available kit for the anti-tTG antibodies' quantitative determination. Design Each centre in this international multi-centre study collected sera from three groups of subjects: coeliac disease patients at the onset of (1) or on a gluten-free diet for at least 12 months (2); disease and healthy controls (3). Methods The anti-tTG antibodies were determined in duplicate using an ELISA-based commercially available kit (Eu-tTG Eurospital, Trieste, Italy). Results The following overall cases and controls have been enrolled: (1) 399 subjects with active coeliac disease; (2) 351 treated coeliac disease cases; (3) 432 controls. The centralized re-testing was performed on: (1) group a: 176 patients with active coeliac disease (mean anti-tTG, 21 arbitrary units [AU]); (2) group b: 172 treated coeliac disease cases (mean anti-tTG, 5 AU); (3) group c: 206 controls (mean anti-tTG, 3 AU). In active coeliacs, the anti-tTG antibodies showed a significant progressive decrease with age, while in controls an opposite trend was found. In active coeliac disease patients, the anti-tTG antibodies were significantly higher in coeliacs with a grade III enteropathy than in those showing a grade II lesion. In treated coeliacs, the mean anti-tTG values were significantly lower in patients strictly adhering to a gluten-free diet than in those reporting dietary transgressions. The sensitivity and the specificity of the Eu-tTG assay were 90% and 96%, respectively. Conclusion The results of this study show that the commercially available test for the anti-tTG antibodies' determination is a reproducible and valuable tool for the diagnosis and follow up of coeliac disease.

KW - Coeliac disease

KW - Screening

KW - Serology

KW - Tissue transglutaminase

UR - http://www.scopus.com/inward/record.url?scp=0034970961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034970961&partnerID=8YFLogxK

U2 - 10.1097/00042737-200106000-00008

DO - 10.1097/00042737-200106000-00008

M3 - Article

C2 - 11434591

AN - SCOPUS:0034970961

VL - 13

SP - 659

EP - 665

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 6

ER -